Buprenorphine Pharmacology and Opioid Neurobiology

March 12, 2019 to March 21, 2019

Jeffrey Fudin, PharmD, FCCP, FASHP, FFSMB
Chief Executive Officer & Chief Medical Officer, REMITIGATE LLC
Clinical Pharmacy Specialist & PGY2 Pain Residency Director
Stratton VA Medical Center (WOC)

Daniela Zaborskis, PhD
Director of Operations and Senior Scientist, Acutis Diagnostics
Specialized in toxicology diagnostics for over 5 years
Former Teaching Fellow at St. John’s University


Learning Objectives

At the end of this presentation, participants should be better able to:

  • Summarize the neurobiology of opioid addictive behavior
  • List various non-drug sources that are commonly associated with addictive behaviors often requiring cognitive behavior therapy
  • Review basic pharmacology as it applies generally to opioids
  • Understand the pharmacology and pharmacokinetics of buprenorphine
  • Define the differences between agonist, partial agonist, agonist/antagonist, and antagonist opioids
  • Identify differences between the various buprenorphine product formulations, and which are used for medication assisted treatment in combination with cognitive behavior therapy


Course summary
Available credit: 
  • 1.00 AANP
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 APA
Course opens: 
Course expires: 
Event starts: 
03/12/2019 - 12:00am
Event ends: 
03/21/2019 - 11:59pm

Available Credit

  • 1.00 AANP
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 APA


Please login or register to take this course.